Actively Recruiting
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Led by National Institute of Neurological Disorders and Stroke (NINDS) · Updated on 2026-05-07
2000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
BTX has been used since the 1980s in support of the research mission of NINDS. Initial studies were focused on expanding the applicability of BTX treatment to movement disorders and exploring new indications. We evaluated the efficacy of an alternative serotype, type F. Under other protocols, we continue to study the physiology of movement disorders and BTX response. The application of BTX therapy to movement disorders requires an understanding of BTX preparation and handling. The treatment must be tailored to the disorder under treatment and to its expression in the individual patient. Users must know the specific techniques of injection, including the use of EMG and ultrasound guidance. This protocol allows us to train physicians in all aspects of the use of BTX. It also provides us with a cohort of patients, receiving a standard method of treatment and with a stable response to BTX injection, for participation in other protocols on movement disorders and on the responses to BTX injection.
CONDITIONS
Official Title
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 2 years and older who have a disorder potentially treatable with botulinum toxin as judged by the physician
- Disorders eligible include dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia
You will not qualify if you...
- Women who are pregnant, planning to become pregnant, or breastfeeding during the study period
- Subjects requiring treatment with an aminoglycoside antibiotic until treatment is complete
- Subjects with paradoxical vocal fold movement with intermittent stridor due to gastroesophageal reflux or emotional disorders if receiving laryngeal injections
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
V
Vivian S Koo
CONTACT
D
Debra J Ehrlich, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here